Can a shot into the tumor help fight breast cancer?
NCT ID NCT07319195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests two immune-boosting drugs—Mitazalimab and Nivolumab—injected directly into breast tumors before surgery. The goal is to see if this approach is safe and can activate the immune system to fight the cancer. About 32 adults with resectable breast cancer will receive one dose 7 or more days before their scheduled surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mitazalimab (CD40 agonist) and Nivolumab (PD-1 inhibitor)
What this could lead to
If successful, this could point toward a new way to activate the immune system against breast cancer before surgery, potentially reducing recurrence risk.
What could go wrong
This is a very early (Phase 1) trial with only 32 participants, so safety and immune effects are still unknown. The treatment may not improve outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••